Results 111 to 120 of about 1,518,675 (340)

COVID‐19 vaccine‐associated myositis – a case report

open access: yesClinical Case Reports, 2022
Myositis is one of the uncommon adverse events following COVID‐19 vaccination, and its mechanism is still unclear. A strong clinical suspicion and further evaluation are important not only for early diagnosis and management but also for better ...
Ponnu Bose   +5 more
doaj   +1 more source

Reasons for COVID-19 Vaccine Hesitancy Among Chinese People Living With HIV/AIDS: Structural Equation Modeling Analysis

open access: yesJMIR Public Health and Surveillance, 2022
BackgroundMany countries and organizations recommended people living with HIV/AIDS (PLWHA) receive the COVID-19 vaccine. However, vaccine hesitancy still exists and becomes a barrier for promoting COVID-19 vaccination among PLWHA.
Yan Yao   +11 more
doaj   +1 more source

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

open access: yesmedRxiv, 2021
Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of vaccine-induced neutralizing antibodies.
W. Garcia-Beltran   +17 more
semanticscholar   +1 more source

Cholesterol Laundry of Cell Membrane and Fatty Liver by Detergent Liposomes to Improve Anti‐Cancer Drug Responsiveness of Patient Liver Tissues

open access: yesAdvanced Science, EarlyView.
Cholesterol‐enriched plasma membranes in hepatocellular carcinoma impede drug penetration. Cholesterol (+)‐liposomes act as membrane‐specific detergents, extracting cholesterol and reducing barrier function without cytotoxicity. Following endocytosis, cholesterol transfers from endosomes to liposomes and is metabolized in the ER.
Chansik Kim   +9 more
wiley   +1 more source

COVID-19 Vaccine: A comprehensive status report

open access: yesVirus Research, 2020
The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2.
Simran Kaur, Vandana Gupta
semanticscholar   +1 more source

COVID-19 Vaccine Acceptance among Health Care Workers in the United States

open access: yesmedRxiv, 2021
Background: Acceptance of any COVID-19 vaccine is an important challenge to address and will play a major role in combating the pandemic. Healthcare workers (HCWs) are amongst the first group to receive the vaccination, so it is important to consider ...
R. Shekhar   +7 more
semanticscholar   +1 more source

The intersection of health inequalities and COVID‐19: Evidence from National Health Insurance Big Data in South Korea

open access: yesAmerican Journal of Community Psychology, EarlyView.
Abstract Health inequalities persist along lines of income and wealth, shaped by unequal access to healthcare, differences in health behaviors, and pre‐existing chronic conditions. The COVID‐19 pandemic further put families in Korea under health strain and worsened their health outcomes.
Jaehyun Nam   +3 more
wiley   +1 more source

Immunological considerations for COVID-19 vaccine strategies

open access: yesNature reviews. Immunology, 2020
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century.
M. Jeyanathan   +5 more
semanticscholar   +1 more source

Lost and Found: Is Olfactory Recovery More Promising After COVID‐19 Than Other Causes, Even 2 Years Later?

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker   +6 more
wiley   +1 more source

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

open access: yesThe Lancet, 2020
Summary Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe ...
F. Zhu   +20 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy